News

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its…

10 months ago

Autonomix Medical, Inc. Selected for Podium Presentation at the 2025 CRT Annual Meeting

Presentation to highlight Autonomix’s catheter-based technology and key findings from lead-in patients in ongoing human clinical trial in pancreatic cancer…

10 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

Conference Call Scheduled for Wednesday, February 26, 2025 at 9:00 AM ETPORTLAND, Maine, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ImmuCell…

10 months ago

Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025

Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash…

10 months ago

Putting Patients First: Why Europe Must Act to Protect Access To Medicines

AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from…

10 months ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb.…

10 months ago

Mainz Biomed Expands into Switzerland with labor team w

Partnership to Launch DNA-Based Colorectal Cancer Screening TestBERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed…

10 months ago

Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis

Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today…

10 months ago

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Media ReleaseCOPENHAGEN, Denmark; February 20, 2025 Approval based on results from two Phase 1/2 EPCORE® clinical trials, which demonstrated strong…

10 months ago

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

BASKING RIDGE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

10 months ago